Agenus

Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe…

LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune…

LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response…

First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and aboveThird AS01 adjuvanted vaccine containing QS-21 STIMULON to…

Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal dateBalstilimab achieved trial endpoints…

LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell…

LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and…